Study of two drugs for advanced lung cancer with HER2 changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two study drugs for a type of lung cancer that has a specific genetic change (HER2). Doctors want to see if this combination can help treat the cancer when it is advanced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced or has spread, and it can't be removed with surgery or treated with standard radiation and chemo.
- You need to have at least one tumor that can be measured on scans.
- You must not have had a prior treatment that targets HER2.
- You must not have significant lung disease or lung inflammation.
- Your organs (like kidneys and liver) and bone marrow must be working well enough — this will be checked with blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This trial tests two medications, trastuzumab rezetecan and adebrelimab, given alone or together, for people with a specific type of stage III lung cancer that has a HER2 change. The goal is to see if these treatments can help control the cancer after standard chemotherapy and radiation.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial tests combining two targeted therapies (an EGFR inhibitor and a HER2-targeted drug) for advanced lung cancer that has both an EGFR mutation and a HER2 change. The goal is to see if this combination works better than current treatments.
This trial tests a drug called trastuzumab deruxtecan (an antibody-drug conjugate) in people with advanced non-small cell lung cancer that has high levels of HER2. The drug is designed to target and kill cancer cells while sparing healthy cells, and the study will see how well it works and how safe it is.
This study tests a targeted medicine (trastuzumab rezetecan) combined with radiation therapy for people with HER2-mutant non-small cell lung cancer that has only a few spots of growth. The goal is to see if this combination controls the cancer and is safe.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.